-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 29 , 2022 , Pfizer announced that the world's first third-generation ALK inhibitor Borrena® ( Lorbrena® , generic name: Lorlatinib Tablets ) was approved by the State Drug Administration for single drug use for the treatment of patients with anaplastic lymphoma kinase ( ALK )-positive locally advanced or metastatic non-small cell lung cancer ( NSCLC ) .
On April 29 , 2022 , Pfizer announced that the world's first third-generation ALK inhibitor Lorbrena ® ( Lorbrena ® , generic name: Lorlatinib Tablets/Lorlatinib Tablets ) was approved by the National Medical Products Administration .
" Today we have reached another major milestone in the history of the treatment of ALK -positive advanced NSCLC ! With the approval of this ground- breaking innovative therapy, Borrena® , patients will live longer and with higher quality, which is what Pfizer is doing .
In China, lung cancer ranks first in morbidity and mortality, and the disease burden is increasing.
" Recently published clinical study data from the American Association for Cancer Research ( AACR ) show that the progression-free survival ( PFS ) of Briner® in the first-line treatment of ALK -positive NSCLC has exceeded three years, demonstrating an unprecedented time for disease progression-free survival .
" Borina® ® is specially developed to penetrate the blood-brain barrier and inhibit resistance mutations caused by other ALK inhibitors, providing an excellent solution for preventing and delaying disease progression .
In July 2020 , Borrena® ® was approved to be imported by the Hainan Provincial Food and Drug Administration as a clinically urgently needed drug.
References
1.
1 ,NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer.
2 ,R.
3 , Mitsudomi T, Suda K, Tomizawa K, et al.
4.
Gouji Toyokawa, et al.
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? Cancer Metastasis Rev DOI 10.
1007/s10555-015-9592-y 4.
Gouji Toyokawa , et al.
Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? Cancer Metastasis Rev DOI 10.
1007/s10555-015-9592-y
Leave a comment here